ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Nasdaq Portfolio Solutions Channel
  2. Pfizer Biohaven Acquisition Sparks Biotech M&A Hope
Nasdaq Portfolio Solutions Channel
Share

Pfizer Biohaven Acquisition Sparks Biotech M&A Hope

Tom LydonMay 12, 2022
2022-05-12

Earlier this week, Pfizer (NYSE:PFE) announced plans to acquire Biohaven Pharmaceutical (NASDAQ:BHVN) for $11.6 billion, sparking hopes of more biotechnology consolidation activity to come.

Pfizer is paying a 33% premium for the maker of Nurtec ODT, a well-known migraine headache treatment. The deal is one of 2022’s first credible signs that blue chip pharmaceutical companies still want to go shopping in the biotech space.

Should the pace of mergers and acquisitions activity increase, the Invesco Nasdaq Biotechnology ETF (IBBQ A-) is among the exchange traded funds that stand to benefit. IBBQ tracks the Nasdaq Biotech Index, which is one of the deepest biotech benchmarks. IBBQ holds 370 stocks, plenty of which reside in mid- or small-cap territory, and plenty of those names could be takeover targets for cash-rich pharma companies.

Jefferies analyst Michael Yee “calculates that the combined market capitalization of all the biotech stocks valued at under $5 billion is around $350 billion. The cash balance of the top 20 biopharma companies combined, meanwhile, is over $300 billion,” reports Josh Nathan-Kazis for Barron’s.

Historically, biotech bear markets aren’t conducive to a brisk pace of takeover activity. Usually, buyers wait until signs emerge that the broader market is firming, but things could be different this time. A couple of reasons underscore that point.

First, biotech stocks, including mid- and small-cap fare, are being drubbed, and their share prices are low. Second, suitors such as Pfizer are flush with cash and facing pipeline and patent cliffs, indicating they could be compelled to go hunting for inexpensive deals.

“We have reached a point where Big Pharma has so much cash they could basically buy the whole smid-cap universe,” Yee wrote. “We note M&A is tough when markets are falling fast …but eventually a few deals could catalyze things back up.”

Arguably, the primary near-term stumbling block to more biotech mergers and acquisitions activity is that rapidly declining share prices on potential targets make it difficult for would-be buyers to properly value takeover candidates. However, that scenario could be allayed if some firmness emerges in equity prices, indicating that credible floors have been put under biotech stocks.

“What’s more, Yee wrote, it would show that the pharma buyers don’t think that the price will be falling any farther. Taken together, that sense of stabilization could give investors the reassurance they need to come back into biotech, and keep buying,” concludes Barron’s.

For more news, information, and strategy, visit the Nasdaq Investment Intelligence Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X